HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients.
about
Carbon nanotubes: an emerging drug carrier for targeting cancer cellsHormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective studyMetastasis: an early event in cancer progression.HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.
P2860
HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
HER2-positive breast cancer pa ...... gative breast cancer patients.
@ast
HER2-positive breast cancer pa ...... gative breast cancer patients.
@en
type
label
HER2-positive breast cancer pa ...... gative breast cancer patients.
@ast
HER2-positive breast cancer pa ...... gative breast cancer patients.
@en
prefLabel
HER2-positive breast cancer pa ...... gative breast cancer patients.
@ast
HER2-positive breast cancer pa ...... gative breast cancer patients.
@en
P2093
P2860
P356
P1476
HER2-positive breast cancer pa ...... gative breast cancer patients.
@en
P2093
Donggeng Liu
Roujun Peng
Shusen Wang
Xiaoyu Teng
Yanxia Shi
Zhongyu Yuan
P2860
P304
P356
10.2147/OTT.S40851
P407
P577
2013-04-09T00:00:00Z